Evidence map›Paper›PMID 41836419›Full record

ArticleFrontiers in immunology2026

Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for the treatment of blastic plasmacytoid dendritic cell neoplasm.

Rita Pfeifer, Sabine Müller, Marcus Nitsche, Melanie Sohmen, Julia Kostyra, Arthur Bister, Cathrin Bleilevens, Janina Brauner, Angela Mekes, Juliane Raasch and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Rita PfeiferMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Sabine MüllerMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Marcus NitscheMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Melanie SohmenMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Julia KostyraMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Arthur BisterMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Cathrin BleilevensMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Janina BraunerMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Angela MekesMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Juliane RaaschMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Dominika LukasMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Jens KopatzMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Wael Al RawashdehMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Marsilius MuesMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
José Alberto Villacorta HidalgoMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Volker HuppertMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Mario AssenmacherMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Nina MökerMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Rimas OrentasLentigen Technology, Inc., a Miltenyi Biotec Company, Gaithersburg, MD, United States.
Congcong ZhangMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent progress in chimeric antigen receptor (CAR) natural killer (NK) cell therapy has demonstrated their promising potential in cancer immunotherapy. However, most current CAR NK cell manufacturing processes utilize open systems with multiple manual steps, making it challenging to maintain consistent therapeutic quality and regulatory compliance for clinical applications. We specifically developed blood dendritic cell antigen 2 (BDCA2)-targeting CAR NK cells for treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Here, we present an automated, current good manufacturing practice (cGMP)-compliant Natural Killer Cell Transduction (NKCT) process for producing clinical-grade CAR NK cells on the CliniMACS Prodigy

Indexed as

Blastic Plasmacytoid Dendritic Cell NeoplasmImmunotherapy, AdoptiveKiller Cells, NaturalReceptors, Chimeric AntigenAnimalsDendritic CellsHumansMiceTransduction, GeneticReceptors, Chimeric Antigenautomated manufacturingBDCA2 CARBPDCNcancer immunotherapyCAR NK cellsCliniMACS Prodigy NKCT

Identifiers

PMID41836419
PMCPMC12982444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.